Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1111/j.1521-0391.2013.12034.x http://scihub22266oqcxt.onion/10.1111/j.1521-0391.2013.12034.x 23952889/?report=reader!4348575!23952889     free     free     free Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 243.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Am+J+Addict 2013 ; 22 (5): 443-52 Nephropedia Template TP {{tp|p=23952889|t=2013. A double-blind placebo-controlled trial of N-acetylcysteine in the treatment of cocaine dependence |pdf=|usr=}}{{23952889}} gab.com Text A double-blind placebo-controlled trial of N-acetylcysteine in the treatment of cocaine dependence JO: Am J Addict http://www.kidney.de/pget.php?&tw=1&pmid=23952889 #FOAvip BACKGROUND: There remains no FDA approved medication for the treatment of cocaine dependence. Preclinical studies and early pilot clinical investigations have suggested that N-acetylcysteine (NAC) may be useful in the treatment of the disorder. OBJECTIVE: The present report assessed the efficacy of NAC in the treatment of cocaine dependence. METHODS: Cocaine-dependent volunteers (n = 111) were randomized to receive daily doses of 1,200 mg of NAC, 2,400 mg of NAC, or placebo. Participants were followed for 8 weeks (up to three visits weekly). At each of these visits, urine samples were collected, along with self-reports of cocaine use. Urine samples were assessed for quantitative levels of benzoylecognine (ie, cocaine metabolite). RESULTS: Overall, the primary results for the clinical trial were negative. However, when considering only subjects who entered the trial having already achieved abstinence, results favored the 2,400 mg NAC group relative to placebo, with the 2,400 mg group having longer times to relapse and lower craving ratings. CONCLUSION: While the present trial failed to demonstrate that NAC reduces cocaine use in cocaine-dependent individuals actively using, there was some evidence it prevented return to cocaine use in individuals who had already achieved abstinence from cocaine. SCIENTIFIC SIGNIFICANCE: N-acetylcysteine may be useful as a relapse prevention agent in abstinent cocaine-dependent individuals. Twit Text FOAVip A double-blind placebo-controlled trial of N-acetylcysteine in the treatment of cocaine dependence ????Am J Addict http://www.kidney.de/pget.php?&tw=1&pmid=23952889 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=23952889 #FOAvip English Wikipedia <ref>{{Cite pmid|23952889}}</ref> A double-blind placebo-controlled trial of N-acetylcysteine in the treatment of cocaine dependence #MMPMID23952889 LaRowe SD; Kalivas PW; Nicholas JS; Randall PK; Mardikian PN; Malcolm RJ Am J Addict 2013[Sep]; 22 (5): 443-52 PMID23952889show ga BACKGROUND: There remains no FDA approved medication for the treatment of cocaine dependence. Preclinical studies and early pilot clinical investigations have suggested that N-acetylcysteine (NAC) may be useful in the treatment of the disorder. OBJECTIVE: The present report assessed the efficacy of NAC in the treatment of cocaine dependence. METHODS: Cocaine-dependent volunteers (n = 111) were randomized to receive daily doses of 1,200 mg of NAC, 2,400 mg of NAC, or placebo. Participants were followed for 8 weeks (up to three visits weekly). At each of these visits, urine samples were collected, along with self-reports of cocaine use. Urine samples were assessed for quantitative levels of benzoylecognine (ie, cocaine metabolite). RESULTS: Overall, the primary results for the clinical trial were negative. However, when considering only subjects who entered the trial having already achieved abstinence, results favored the 2,400 mg NAC group relative to placebo, with the 2,400 mg group having longer times to relapse and lower craving ratings. CONCLUSION: While the present trial failed to demonstrate that NAC reduces cocaine use in cocaine-dependent individuals actively using, there was some evidence it prevented return to cocaine use in individuals who had already achieved abstinence from cocaine. SCIENTIFIC SIGNIFICANCE: N-acetylcysteine may be useful as a relapse prevention agent in abstinent cocaine-dependent individuals. |Acetylcysteine/adverse effects/*therapeutic use[MESH] |Adult[MESH] |Amino Acid Transport System y+/*drug effects[MESH] |Cocaine-Related Disorders/*drug therapy[MESH] |Double-Blind Method[MESH] |Female[MESH] |Humans[MESH] |Male[MESH] |Psychiatric Status Rating Scales[MESH] |Psychological Tests[MESH] |Secondary Prevention[MESH]A double-blind placebo-controlled trial of N-acetylcysteine in the tre(epmc).pdf DeepDyve Pubget Overpricing